GlassScriptPhysician profile
Richard E Otto
NPI 1730266420
$10,747.12
in general payments reported to CMS, 2019-2025
60 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,523 · 2020: $1,792 · 2021: $1,727 · 2022: $1,450 · 2023: $1,231 · 2024: $1,879 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,255.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,267.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,178.89 | 2019-2025 | Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $742.85 | 2019-2025 | Rexulti |
| Lilly USA, LLC | $659.27 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $639.27 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $616.82 | 2021-2024 | |
| Pfizer INC. | $574.66 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $475.41 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.37 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $408.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $281.87 | 2019-2023 | Xarelto |
| Abbott Laboratories | $257.28 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Astellas Pharma US INC | $247.44 | 2019-2025 | Veozah |
| Allergan, INC. | $231.42 | 2019-2020 | |
| Corium, LLC | $219.48 | 2022-2025 | Azstarys |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Otto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.